Short description
A digital health platform that uses analysis of eye-movements as a biomarker to assess brain health across neurological disorders.
Description
Eysz is developing a digital health platform that measures disease progression, intervention efficacy and side effects to assist clinicians in developing a personalized care plan for neurological diseases. Doctors currently rely on patient self-reported data and subjective clinical exams to manage and treat chronic neurological disorders. The lack of a reliable biomarker in neurological disease leads to economic burdens of $1.7T in the US and Europe alone and stagnant patient outcomes with no significant improvement in outcomes in the last 30 years. Eysz is using analysis of eye-movements as a biomarker to assess brain health across neurological disorders starting with epilepsy – a disorder characterized by recurrent seizures. After completing a successful clinical study sponsored by the NIH and NSF Eysz will be releasing their first product to diagnose and monitor childhood absence epilepsy in Q3 2023.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Piedmont, California, United States, North America
Founded on
January 1, 2018
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Cannot Access, Noaccess, Nopepepe, Noway Youcantaccess, Noaccessforu, No Way, Noaccess, Absolutely Noaccess, Uh Ohhhh
Sign in for full access
Founders
Rachel Kuperman, Randy Berholtz